Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FormBlends vs Lavender Sky Health

FormBlends
Graded #75

Higher grade

vs+4
Lavender Sky Health
Graded #138

Lower grade

The verdict

FormBlends takes it — 72.7/100 to 68.7/100.

FormBlends grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FormBlends is a US direct-to-consumer brand selling compounded GLP-1 weight-loss medication — compounded semaglutide from $99 and compounded tirzepatide from $349 — dispensed by a licensed 503A pharmacy and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFormBlends +8
84
76
Dose & formulationFormBlends +13
77
64
Clinical oversightFormBlends +2
76
74
Labs & monitoringLavender Sky Health +1
52
53
FulfillmentLavender Sky Health +7
74
81
Contract termsEven
55
55
FormBlends · left barLavender Sky Health · right bar

The numbers

MetricFormBlendsLavender Sky Health
WeighScore72.7/10068.7/100
GradeCC
Scorecard rank#75#138
Semaglutide$99/mo (compounded)$139/mo (starting dose, month to month, Southend Pharmacy, compounded)
Tirzepatide$349/mo (compounded)$149/mo (starting dose, month to month, ReviveRx, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
FormBlends

Graded #75 · C

Strengths

  • Low published entry price on compounded semaglutide ($99) from a licensed 503A pharmacy
  • Physician-supervised program with 24/7 care-team access and free shipping over $150
  • Extensive free educational content, guides and provider comparisons on-site

Where it loses points

  • Enrollment and final pricing complete on an external portal (rx.formscripts.com), not fully on-site
  • $99 may be an intro rate; tirzepatide is comparatively high at $349/mo
  • State availability and LegitScript status not published; pharmacy is its own FormScripts brand
Lavender Sky Health

Graded #138 · C

Strengths

  • The treatment-plan pricing page publishes every pharmacy's full ladder rather than one headline figure, so the cheaper prepaid tiers are visible alongside the monthly ones
  • A genuine month-to-month starter plan exists with no prepay, and the cheapest of them is what is filed above — Southend for semaglutide, ReviveRx for tirzepatide
  • Compounded plans include the price of the medication, and shipping and supplies are stated as included
  • Both semaglutide and tirzepatide are offered, across roughly ten named compounding pharmacies

Where it loses points

  • This is a marketplace, not one price: every figure belongs to a named pharmacy on a named plan, and the pharmacy and plan have to travel with the number for it to mean anything
  • Most of the ladder is prepaid — Tier plans need 8-10 weeks up front and Extended plans 3-4 months — and only a handful of the pharmacies publish a month-to-month starter plan at all
  • Brand-name plans add a separate $25 monthly treatment-plan fee and explicitly do not include the price of the medication; only the compounded plans include it
  • No price appears on the homepage, and the pricing page is the only place the ladders are published
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard